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Reverse transcription (RT)-PCR is now the standard method for typing group A rotaviruses (RVA) to monitor the
circulating genotypes in a population. Selection of primers that can accurately type the circulating genotypes is
crucial in the context of vaccine introduction and correctly interpreting the impact of vaccination on strain
distribution. To our knowledge this study is the first report from Asia of misidentification of genotype G9 as G3 due
to a primer-template mismatch. We tested two published G-genotype specific primers sets, designed by Gouvea
and colleagues (Set A) and Iturriza-Gomara and colleagues (Set B) on RVA from Hong Kong and Sri Lanka. Among
52 rotaviruses typed as G3 by set A primers, 36 (69.2%) were identified as G9 by nucleotide sequencing and set B
primers. Moreover, of 300 rotaviruses tested, 28.3% were untypable by set A primers whereas only 12.3% were
untypable by set B primers. Our findings reinforce the need to periodically monitor the primers used for
RVA genotyping.
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Every year rotavirus infects 114 million children and
accounts for about 453,000 deaths mainly in developing
countries [1,2]. RVA is a non-enveloped virus with a
triple-layered wheel-like capsid containing 11 segments
of double stranded RNA in its core. VP7 and VP4 nu-
cleotide sequence define the G and P genotypes, respect-
ively [3]. These proteins have independent neutralization
properties and are used in a binary classification system.
Of the 27 G and 35 P types thus far identified by
molecular characterization [4], 12 G and 15 P types have
been detected in humans [3]. Globally, G1 through G4
and G9 are the most common types causing human
infection [5]. The primary goal of most RVA strain sur-
veillance has been to determine the circulating genotypes
for the introduction of vaccine and to monitor vaccine
effectiveness [6].
RT-PCR is the method of choice for typing rotaviruses
and is regarded as the gold standard [7]. The accumula-
tion of point mutations at primer binding sites has
been linked with mistyping or failure to identify genotype* Correspondence: ahmed@oita-u.ac.jp
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reproduction in any medium, provided the orcorrectly. To maintain the accuracy, primers used in
PCR-based typing methods need to be regularly revised
and updated [8]. In 1990, a multiplexed hemi-nested RT-
PCR based G genotyping assay was developed by Gouvea
and colleagues [9]. This assay, correlated well with an
antibody-based G-serotyping system. Subsequently, pri-
mers proposed by Das et al. [10] and Iturriza-Gómara
et al. [11] for G genotyping assays were introduced.
In our laboratory we used primers designed by Gouvea
et al., for genotyping RVA from different countries and
satisfactory results were obtained when RT-PCR results
were compared with VP7 gene sequence information.
We regularly validated the results of PCR with VP7
sequence results and, during genotyping of RVA from
Sri Lankan samples, it was identified that many of the
genotype G9 rotaviruses were typed as G3 by PCR.
G9 strains started to be reported in the mid-1990s
from India, Japan, the United Kingdom, and the United
States [12]. Subsequently, these strains spread globally
and they are now the third most common genotype of
RVA. In recent years the G9 rotaviruses have also shown
increasing genomic diversity within the genotype [13].
An overall increase in G3 strains has recently being
reported from many countries [14-16], some of them ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RVA vaccine [17,18]. How vaccine pressure has resulted
in emergence of this genotype is unknown, but sus-
tained and accurate monitoring is clearly desirable to
clarify this.
Since both G9 and G3 are very important considering
the current epidemiology of genotype distribution,
we extended the experiment to all samples from
Sri Lanka and Hong Kong and determined that alternate
primers set designed by Iturriza-Gomara et al. (2004)
[11] gave us satisfactory results. Considering the import-
ance of this finding we are reporting the results to
aware researchers.
A total of 422 stool samples positive for RVA were
obtained from children under 5 years of age who
attended major hospitals in Hong Kong and Sri Lanka
for diarrhea: 300 from Hong Kong (December 2004
through December 2005); 122 from Sri Lanka (April
2005 through October 2006). These samples were
collected as part of rotavirus surveillance [14,19].
Approval was obtained from the Ethical Review Board of
Sri Lankan College of Pediatrics. Hong Kong samples
were the remaining portion of specimens submitted for
tests because of clinical indication, therefore approval
was not required. All samples were delinked from per-
sonal identifiers.
RVA was detected using the commercially available
ELISA kits according to manufacturer’s instructions:
IDEIA Rotavirus (Dako Diagnostics, Cambridgeshire,
UK) in Hong Kong; and Rotaclone (Meridian Bioscience
Inc., Cincinnati, OH) in Sri Lanka. The nucleic acids
were extracted by the phenol- chloroform-isoamyl
alcohol method.
We used one step RT-PCR targeting the VP7 gene of
RVA. PCR primers were Beg9 and End9 [9]. A commer-
cial master mix formulation, AccessQuick™ RT-PCR
System (Promega Corporation, Madison, WI, USA) was
employed. Each reaction contained 25 μl of Access-
Quick™ Master Mix, 1 μl of each primer at a final con-
centration of 0.2 μM, 2 μl of the dsRNA template, 1 μl
of reverse transcriptase, and nuclease-free water to a
final volume of 50 μl. For RT, incubation was at 45°C forTable 1 Primer comparison between Gouvea et al. and Iturriz
are different
Primers of Gouvea et al. (Set A)






Primers for G1, G2 and G4 in Iturriza-Gomara et al. were adapted from primers of G45 minutes and the contiguous PCR conditions were as
follows: 95°C for 1 minute, followed by 40 cycles at 94°C
for 1 minute, 50°C for 1 minute, 72°C for 1 minute 30
seconds and a final extension at 72°C for 5 minutes.
In this study, the G type was identified by hemi-nested
multiplex PCR method with genotype specific primers
for G1, G2, G3, and G4 proposed by Gouvea et al. [9]
(designated “set A”) and by nested multiplex PCR
method with genotype specific primers for G1, G2, G3,
G4 and G9 proposed by Iturriza-Gómara et al. [11]
(designated “set B”)(Table 1). For both sets of primers,
PCR was carried out by the PCR Master Mix (Promega
Corporation), as follows: each reaction contained 25 μl
of PCR Master Mix, 1 μl of each primer at a final con-
centration of 0.2 μM, 1 μl of the VP7 amplicon, and
nuclease-free water to a final volume of 50 μl. PCR con-
ditions were as follows: 30 cycles at 95°C for 1 minute,
42°C for 2 minutes and 72°C for 1 minutewith a final
extension step at 72°C for 5 minutes.
The nucleotide sequence of the VP7 gene was deter-
mined by Big Dye terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster city, CA, USA) and the
product was subjected to an ABI Prism 3130 Genetic
Analyzer (Applied Biosystems) [12]. The VP7 gene
sequence similarity was searched by BLAST to deter-
mine the G types. The genotype of each strain deter-
mined by different sets of primers was compared with
corresponding nucleotide sequence.
Of the 52 RVA typed as G9 by nucleotide sequencing
of the VP7 gene, 36 (69.2%) (3 from Hong Kong and 33
from Sri Lanka) were typed as G3 by set A primers.
To determine the identity between the primers and
the nucleotide sequences of the gene, the G3 and G9
primers of both set A and B were aligned with the
nucleotide sequence of the VP7 gene of G9 strains
(3 from Hong Kong and 22 from Sri Lanka) (Figure 1).
The G3 and G9 primers of set A showed 76% (16/21nt)
and 85% (17/20nt) identity, whereas the G3 and G9 pri-
mers of set B had 58% (11/19nt) and 100% (20/20) iden-
tity, respectively.
Aligning the G3 primers of set A with the VP7 gene
sequences of G9 strains revealed eight consecutivea-Gomara et al. Note that primer for G3 and G9
Primers of Iturriza-Gomara et al. (Set B)







Figure 1 Multiple alignments of the VP7 gene sequences of G9 rotaviruses from Hong Kong and Sri Lanka with the corresponding G3
and G9 specific primers proposed by Gouvea et al. and Iturriza-Gómara et al. Dots indicate consensus with the primer.
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nucleotide identities next to the 3′ end. This could
explain the mismatched primer binding and as a conse-
quence the incorrect genotyping.
G3 forward primer of set A was derived from residues
689 to 709 nt of the VP7 gene of G3 RVA generating a
PCR product of 374 bp, but it also anneals with the
same residues of the VP7 gene of G9 RVA, generating a
PCR product of the same length and indistinguishableafter running the gel electrophoresis. G3 forward primer
of set B was derived from residues 250 to 269 nt of the
VP7 gene of G3 rotavirus generating a PCR product of
682 bp.
To verify the accuracy of set B primers, typing was
done on five G9 and five G3 strains. The types of these
strains were confirmed by nucleotide sequencing. All
were typed correctly by set B primers but identified
as genotype G3 by set A primers.
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Hong Kong were subjected to typing by both sets of
primers, 80 strains were typed as G3 by both sets of
primers. However, nine G9 strains typed as G3 by set A
primers were correctly typed by set B primers, show-
ing a 10.1% chance of mistyping (G9 as G3) by set A
primers. Of 300 rotaviruses tested, 28.3% were untyp-
able by set A primers whereas only 12.3% were untyp-
able by set B primers. These untypables were typed
by the VP7 gene sequencing and no primer mismatch
was found indicating possible contaminants which
hindered PCR.
RT-PCR genotyping failure is a hindrance in RVA
research, generally ranging 10–30%, and tends to be
higher in samples from developing countries [20]. This
problem has often been attributed to single nucleotide
polymorphisms at the primer binding sites [21-25]. The
occurrence of erroneous typing among strains due to
mismatched primers deserves special consideration.
Reported RVA primers mismatches identified genotype
G8 as G12 and G3 as G10 [25-27]. To our knowledge
this is the first report from Asia of G9 being mistyped as
G3 [28], since both are prevalent genotypes worldwide,
this information will be crucial for accurate surveillances.
Gouvea et al. [9] and Iturriza-Gómara et al. [11] pro-
posed the primers for G genotyping in 1990 and 2004,
respectively. It is plausible that rotaviruses have high
mutation rates even in sites that are considered well
conserved. It is therefore essential that widely used pri-
mers sets, particularly those developed some while back,
be re-evaluated on a regular basis to ensure that circulat-
ing RVA strains are accurately typed.
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